Cotización Panacea Acquisition - NUVB

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

2.87

Postura de Compra

Postura de Venta

Volume Operado de la Acción

2,772,827

2.45 Rango del Día 2.70

1.21 Rango de 52 semanas 4.1598

Capitalización de Mercado [m]

715.334M

Precio Anterior

2.54

Precio de Apertura

2.58

Hora

122

2.87

(formt)

Última hora de negociación

Volumen financiero

US$ 7,219,410

Precio Promedio Ponderado

2.6036

Volumen promedio (3 m)

1,550,974

Acciones en circulación

249,245,129

Rendimiento del Dividendo

Ratio Precio/Utilidad

-8.58

Beneficio por acción (BPA)

-0.3

turnover

Beneficio neto

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

ecor1cap.com

Sede

Wilmington, Delaware, USA

Fundado

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was US$2.54. Over the last year, Panacea Acquisition shares have traded in a share price range of US$ 1.21 to US$ 4.1598.

Panacea Acquisition currently has 249,245,129 shares in issue. The market capitalisation of Panacea Acquisition is US$633.08 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -8.58.

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of patients with advanced ROS1-positive (ROS1+) non-small cell...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:...

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (TKI)-naïve and 56% of those who...

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...

Form 4 - Statement of changes in beneficial ownership of securities

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.56	24.2424242424	2.31	2.98	2.18	1777246	2.35419605	CS
4	0.71	32.8703703704	2.16	2.98	2	1560311	2.33720763	CS
12	0.06	2.13523131673	2.81	3.3986	2	1550974	2.60363083	CS
26	-0.32	-10.0313479624	3.19	3.97	2	1522467	2.88246219	CS
52	1.54	115.789473684	1.33	4.1598	1.21	1334329	2.64763358	CS
156	-6.33	-68.8043478261	9.2	10.45	0.95	1016106	3.16198346	CS
260	-7.13	-71.3	10	15.23	0.95	971720	4.41210972	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
DXYZDestiny Tech100 Inc	US$ 22.20 (39.71%)	12.2M
WWWWolverine World Wide Inc	US$ 21.81 (35.89%)	5.9M
IONQIonQ Inc	US$ 22.11 (34.41%)	70.44M
FREYFREYR Battery Inc	US$ 2.341 (33.77%)	24.34M
QBTSD Wave Quantum Inc	US$ 1.45 (28.32%)	21.09M
WOLFWolfspeed Inc	US$ 8.28 (-39.61%)	46.15M
LEVLion Electric Company	US$ 0.4219 (-25.98%)	2.17M
YOUClear Secure Inc	US$ 28.48 (-25.93%)	10.24M
MATVMativ Holdings Inc	US$ 13.73 (-21.09%)	684.99k
JMIAJumia Technologies AG	US$ 4.0097 (-16.81%)	7.15M
PLTRPalantir Technologies Inc	US$ 55.88 (0.63%)	121.58M
IONQIonQ Inc	US$ 22.11 (34.41%)	70.88M
NIONIO Inc	US$ 5.31 (6.20%)	56.49M
FFord Motor Company	US$ 10.95 (-2.14%)	55.38M
VALEVale SA	US$ 11.21 (3.80%)	51.31M